{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:12:17Z","timestamp":1789992737944,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013459","name":"Arthritis New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.semarthrit.2026.153078","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:28:36Z","timestamp":1789399716000},"page":"153078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cyclophosphamide vs rituximab induction therapy for ANCA-associated vasculitis. A systematic review and meta-analysis of 12-month mortality"],"prefix":"10.1016","volume":"81","author":[{"given":"Caroline","family":"Allan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursimran","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa K","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/art.20082","article-title":"Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients","volume":"51","author":"Bligny","year":"2004","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153078_bib0002","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/ker112","article-title":"Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence","volume":"50","author":"Corral-Gudino","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153078_bib0003","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/ndt\/13.7.1713","article-title":"Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis","volume":"13","author":"Haubitz","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"5 Suppl 51","key":"10.1016\/j.semarthrit.2026.153078_bib0004","first-page":"S94","article-title":"Mortality in systemic vasculitis: a systematic review","volume":"26","author":"Phillip","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/03009740903140701","article-title":"Survival of patients with Wegener's granulomatosis diagnosed in Finland in 1981-2000","volume":"39","author":"Takala","year":"2010","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153078_bib0006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153078_bib0007","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","article-title":"Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies","volume":"76","author":"Tan","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153078_bib0008","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153078_bib0009","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153078_bib0010","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0011","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153078_bib0012","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153078_bib0013","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153078_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153078_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term Rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153078_bib0016","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0017","article-title":"Cyclophosphamide vs rituximab \u2013 impact on mortality in ANCA-associated vasculitis","author":"Kaur","year":"2022","journal-title":"A systematic review and meta-analysis"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153078_bib0018","doi-asserted-by":"crossref","first-page":"531","DOI":"10.5195\/jmla.2018.283","article-title":"A systematic approach to searching: an efficient and complete method to develop literature searches","volume":"106","author":"Bramer","year":"2018","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0019","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153078_bib0020","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0021","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0022","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0026","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12882-015-0091-8","article-title":"ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study","volume":"16","author":"Andreiana","year":"2015","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153078_bib0027","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejim.2010.09.005","article-title":"Long-term follow-up of microscopic polyangiitis, 17-year experience at a single center","volume":"21","author":"Borao-Cengotita-Bengoa","year":"2010","journal-title":"Euro J Int Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153078_bib0028","first-page":"686","article-title":"Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153078_bib0029","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheumatol"},{"issue":"Supplement 1","key":"10.1016\/j.semarthrit.2026.153078_bib0030","first-page":"i334","article-title":"Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis with renal involvement: a single center experience","volume":"38","author":"Dias","year":"2023","journal-title":"Nephro Dial Trans"},{"issue":"SUPPL. 70","key":"10.1016\/j.semarthrit.2026.153078_bib0031","first-page":"S39","article-title":"Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis","volume":"30","author":"Gregersen","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153078_bib0032","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0033","first-page":"93","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153078_bib0034","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153078_bib0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ndt\/gfs428","article-title":"Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study","volume":"28","author":"Hilhorst","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105883","article-title":"The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis","volume":"76","author":"Huang","year":"2019","journal-title":"Int Immunopharmacolo"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153078_bib0038","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153078_bib0039","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00296-004-0499-0","article-title":"Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients","volume":"26","author":"Kamali","year":"2005","journal-title":"Rheumatolo Int"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153078_bib0041","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3899\/jrheum.090387","article-title":"Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients","volume":"37","author":"Kamali","year":"2010","journal-title":"J Rheumatol"},{"issue":"SUPPL. 1","key":"10.1016\/j.semarthrit.2026.153078_bib0042","doi-asserted-by":"crossref","first-page":"i382","DOI":"10.1093\/ndt\/gfw185.12","article-title":"Outcome and immunosuppressive treatment of elderly patients with ANCA-associated vasculitis","volume":"31","author":"Kato","year":"2016","journal-title":"Nephrolo Dial Trans"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153078_bib0043","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10067-017-3944-7","article-title":"Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis","volume":"37","author":"La-Crette","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153078_bib0044","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3899\/jrheum.131426","article-title":"Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients","volume":"41","author":"Lai","year":"2014","journal-title":"J Rheumatol"},{"issue":"22","key":"10.1016\/j.semarthrit.2026.153078_bib0045","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2169\/internalmedicine.52.0199","article-title":"Long-term outcome and efficacy of cyclophosphamide therapy in Japanese patients with ANCA-associated microscopic polyangiitis: a retrospective study","volume":"52","author":"Nakaya","year":"2013","journal-title":"Int Med"},{"issue":"SUPPL. 3","key":"10.1016\/j.semarthrit.2026.153078_bib0046","first-page":"iii192","article-title":"Treatment of pauci-imune vasculitis with a reduced IV cyclophosphamide regimen","volume":"29","author":"Nunes","year":"2014","journal-title":"Nephrol Dial Trans"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153078_bib0047","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/RHU.0b013e31828632a3","article-title":"Clinical features and outcomes of 37 argentinean patients with severe granulomatosis with polyangiitis (Wegener Granulomatosis)","volume":"19","author":"Orden","year":"2013","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153078_bib0048","first-page":"1299","article-title":"Outcome and prognostic factors during the course of primary small-vessel vasculitides","volume":"33","author":"Pavone","year":"2006","journal-title":"J Rheumatol"},{"issue":"Supplement 3","key":"10.1016\/j.semarthrit.2026.153078_bib0049","doi-asserted-by":"crossref","first-page":"iii104","DOI":"10.1093\/rheumatology\/kex128","article-title":"Management and outcomes of ANCAassociated vasculitis in unselected new cases within a large health region of England","volume":"56","author":"Pearce","year":"2017","journal-title":"Rheumatology (United Kingdom)"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153078_bib0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2215\/CJN.03680412","article-title":"Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis","volume":"8","author":"Pepper","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"34","key":"10.1016\/j.semarthrit.2026.153078_bib0051","article-title":"Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Pyo","year":"2021","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.777134","article-title":"Treating patients with ANCA-associated vasculitis and very severe renal injury with an intensified B cell depletion therapy: comparison with a control cohort receiving a conventional therapy","volume":"13","author":"Roccatello","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153078_bib0053","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1445-5994.1993.tb01812.x","article-title":"Wegener's granulomatosis: clinical features and prognosis in 37 patients","volume":"23","author":"Romas","year":"1993","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0054","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmunity"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153078_bib0055","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1136\/ard.2010.131953","article-title":"Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153078_bib0056","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1046\/j.1523-1755.2003.00769.x","article-title":"Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement","volume":"63","author":"Slot","year":"2003","journal-title":"Kidney Int"},{"issue":"4 PART 2","key":"10.1016\/j.semarthrit.2026.153078_bib0057","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.lpm.2013.02.240","article-title":"Long-term outcome of low dose cyclophosphamide (CYC) and plasma exchange (PLEX) induction in ANCA-associated vasculitis (AAV)","volume":"42","author":"Szpirt","year":"2013","journal-title":"Presse Medicale"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153078_bib0058","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153078_bib0059","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ndt\/gfh161","article-title":"ANCA-associated vasculitis with renal involvement: an outcome analysis","volume":"19","author":"Weidner","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"3 Supplement 1","key":"10.1016\/j.semarthrit.2026.153078_bib0060","first-page":"S148","article-title":"ANCA-associated vasculitis (AAV): rituximab and its clinical use and roles in a hospital-based vasculitis cohort","volume":"24","author":"Bankole","year":"2018","journal-title":"J Clinical Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153078_bib0061","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/ard-2023-224343","article-title":"Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study","volume":"83","author":"Furuta","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153078_bib0062","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153078_bib0063","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3349\/ymj.2020.61.8.712","article-title":"Rituximab biosimilar prevents poor outcomes of microscopic polyangiitis and granulomatosis with polyangiitis as effectively as rituximab originator","volume":"61","author":"Kwon","year":"2020","journal-title":"Yonsei Med J"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153078_bib0064","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0065","article-title":"Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: a retrospective study","volume":"6","author":"Ysermans","year":"2023","journal-title":"J Trans Autoimmunity"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153078_bib0066","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Eng J Med"},{"issue":"Supplement 1","key":"10.1016\/j.semarthrit.2026.153078_bib0067","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/annrheumdis-2022-eular.3481","article-title":"Mortality trends in ANCA-associated vasculitides (AAVS): data from a contemporary multicenter ANCA registry","volume":"81","author":"Koutsianas","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153078_bib0068","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","article-title":"Long-term outcomes in elderly patients with ANCA-associated vasculitis","volume":"59","author":"McGovern","year":"2020","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2026.153078_bib0069","unstructured":"Specks, U., et al., Efficacy of remission-induction regimens for ANCA-associated vasculitis. 2013. 369(5): p. 417\u201327."},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153078_bib0070","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.42515","article-title":"Comparative effectiveness of Rituximab- versus cyclophosphamide-based remission induction strategies in antineutrophil cytoplasmic antibody-associated vasculitis for the risk of kidney failure and mortality","volume":"75","author":"Wallace","year":"2023","journal-title":"Arthrits Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153078_bib0023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Eng J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153078_bib0024","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153078_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis","volume":"5","author":"Pu\u00e9chal","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722600168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722600168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:37:13Z","timestamp":1789990633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722600168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":70,"alternative-id":["S004901722600168X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153078","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide vs rituximab induction therapy for ANCA-associated vasculitis. A systematic review and meta-analysis of 12-month mortality","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153078"}}